Exploratory Study to Assess the Effect of Fampridine (BIIB041) on Walking Ability and Balance in Participants With Multiple Sclerosis. (MOBILE)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Biogen Idec
ClinicalTrials.gov Identifier:
NCT01597297
First received: May 10, 2012
Last updated: July 17, 2014
Last verified: July 2014
  Purpose

The objectives of this study in Multiple Sclerosis (MS) participants treated with prolonged-released fampridine (BIIB041) 10 mg twice daily compared with participants treated with placebo are to assess the effect over 24 weeks on the following parameters to explore endpoints for the Phase 3 study: self-assessed walking disability, dynamic and static balance, subjective impression of well-being, and participants' global impression of change in walking . Another purpose of this study is to evaluate the safety and tolerability of prolonged-release fampridine.


Condition Intervention Phase
Multiple Sclerosis
Drug: BIIB041 (PR Fampridine)
Other: Placebo
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Exploratory Study to Assess the Effect of Treatment With Prolonged-Release Fampridine (BIIB041) 10 mg Twice Daily on Walking Ability and Balance in Subjects With Multiple Sclerosis

Resource links provided by NLM:


Further study details as provided by Biogen Idec:

Primary Outcome Measures:
  • Change from baseline in self-assessed walking disability as reported on the Multiple Sclerosis Walking Scale-12 (MSWS-12) [ Time Frame: Day 1, up to 24 weeks ] [ Designated as safety issue: No ]
  • Change from baseline in static balance as assessed by Berg Balance Scale (BBS) [ Time Frame: Day 1, up to 24 weeks ] [ Designated as safety issue: No ]
  • Change from baseline in dynamic balance as assessed by the Timed Up and Go (TUG) scale) [ Time Frame: Day 1, up to 24 weeks ] [ Designated as safety issue: No ]
  • Change from baseline in subjective impression of well-being measured by Multiple Sclerosis Impact Scale-29 (MSIS-29) [ Time Frame: Day 1, up to 24 weeks ] [ Designated as safety issue: No ]
  • Change from baseline in subjective impression of well-being measured by Euro Quality of Life-5D (EQ-5D) [ Time Frame: Day 1, up to 24 weeks ] [ Designated as safety issue: Yes ]
  • Participant's global impression of change in walking as reported on the Patient Global Impression of Change Scale (PGIC) [ Time Frame: Day 1, up to 24 weeks ] [ Designated as safety issue: No ]
  • Summary of Participants with adverse events (AEs) and serious adverse events (SAEs) [ Time Frame: Day 1 Up to 26 weeks ] [ Designated as safety issue: Yes ]

Enrollment: 132
Study Start Date: August 2012
Study Completion Date: August 2013
Primary Completion Date: August 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Fampridine-PR
Prolonged-Release Fampridine (Fampridine-PR) 10 mg twice daily (every 12 hours) for up to 24 weeks.
Drug: BIIB041 (PR Fampridine)
10 mg twice daily, given orally. Doses of study treatment must be spaced at least 12 hours apart. If a dose of study treatment is delayed or missed, the participant should not dose again until their next scheduled dose. Tablets must be swallowed whole and should be taken without food.
Other Names:
  • Fampridine-PR (prolonged-release)
  • Dalfampridine-ER (extended-release)
  • FAMPYRA®
  • AMPYRA®
Placebo Comparator: Placebo
Matched placebo twice daily (every 12 hours) for up to 24 weeks.
Other: Placebo
Twice daily, given orally. Doses of study treatment must be spaced at least 12 hours apart. If a dose of study treatment is delayed or missed, the participant should not dose again until their next scheduled dose. Tablets must be swallowed whole and should be taken without food.

Detailed Description:

The primary objective of the study is to explore the effect of prolonged-released fampridine 10 mg twice daily in patients with Multiple Sclerosis with walking disability. The change of walking ability will be measured using Multiple Sclerosis Walking Scale-12 (MSWS-12) to further elucidate the clinical relevance of changes over 24 weeks treatment duration. Another purpose of this study is to evaluate the safety and tolerability of prolonged-release fampridine.

Approximately 120 patients MS will be randomized over 20 sites worldwide. Duration of patient's participation in the study will be approximately 28 weeks.

  Eligibility

Ages Eligible for Study:   18 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Key Inclusion Criteria:

  • Must be able to understand the purpose and risk of the study and provide signed and dated informed consent and authorization to use protected health information (PHI) in accordance with national and local subject privacy regulations
  • Diagnosis of primary-progressive, secondary progressive, progressive-remitting, or relapsing-remitting Multiple Sclerosis of at least 3-month duration
  • EDSS 4 to 7
  • Female patients of childbearing potential must practice effective contraception during the study and be willing and able to continue contraception for 30 days after their last dose of study treatment
  • Must be able to understand and comply with the requirements of the protocol

Key Exclusion Criteria:

  • Known allergy to pyridine-containing substances or to any of the inactive ingredients in the prolonged release fampridine (BIIB041) tablet
  • Any history of seizure, epilepsy, or other convulsive disorder, with the exception of febrile seizures in childhood
  • An estimated creatinine clearance (CrCl) of <80 mL/minute (using the Cockcroft-Gault formula)
  • Known history of Human Immunodeficiency Virus, hepatitis C, or hepatitis B. Subjects who have evidence of prior hepatitis infection that has been serologically confirmed as resolved based on previous testing documented in the subjects' medical history are not excluded from study participation
  • History of malignant disease including solid tumors and hematologic malignancies (with the exception of basal cell and squamous cell carcinomas of the skin that have been completely excised and are considered cured) within the 5 years prior to the Screening Visit, or at any time during the screening period
  • Onset of MS exacerbation within the 60 days prior to the Screening Visit, or at any time during the screening period
  • History of any major surgical intervention (with the exception of skin biopsy) within the 30 days prior to the Screening Visit, or at any time during the screening period
  • Any non-MS-related condition or factor (as determined by the Investigator) that is likely to interfere with walking ability including, but not limited to, previous major surgery of the foot, leg, or hip; any significant trauma; or known peripheral neuropathy of the lower limb
  • Presence of pulmonary disease including, but not limited to, chronic obstructive pulmonary disease that could impede the subject's daily activities (as determined by the Investigator)
  • Presence of any psychiatric disorder, including clinical depression, that is likely to interfere with the subject's participation in the study (as determined by the Investigator)
  • Uncontrolled hypertension (as determined by the Investigator) at the Screening Visit, any time during the screening period, or Day 1
  • History of any clinically significant endocrinologic, hematologic, immunologic, metabolic, urologic, neurologic (except for MS, but including events indicative of a potentially lower seizure threshold), dermatologic, or other major disease (as determined by the Investigator)
  • Clinically significant abnormal laboratory values (as determined by the Investigator)
  • A Body Mass Index ≥40
  • Use of off label MS treatment including rituximab, alemtuzumab, daclizumab, or antibody (except natalizumab) within the 3 months prior to the Screening Visit, or any time during the screening period, or scheduled use during study participation
  • Use of mitoxantrone or cyclophosphamide within the 3 months prior to the Screening Visit, or any time during the screening period, or scheduled use during study participation
  • Initiation of natalizumab treatment or any change in the subject's dose or regimen of natalizumab, within the 3 months prior to the Screening Visit, or at any time during the screening period
  • Initiation of treatment with, or any change in the subject's dose or regimen of, interferon β 1b, interferon β-1a, fingolimod, or glatiramer acetate within the 30 days prior to the Screening Visit, or at any time during the screening period
  • Pulsed steroid treatment within the 60 days prior to the Screening Visit, or at any time during the screening period
  • Any change in the subject's medication dose or regimen for the treatment of fatigue or depression within the 30 days prior to the Screening Visit, or at any time during the screening period
  • Any change in prophylactic treatment for pain with antidepressants or anticonvulsants prescribed for this purpose within 30 days prior to the Screening Visit, or at any time during the screening period
  • Any change in the subject's dose or regimen of antispastic agents within the 7 days prior to the Screening Visit, or at any time during the screening period
  • Treatment with an investigational drug or approved therapy for investigational use within the 30 days (or 7 half-lives, whichever is longer) prior to the Screening Visit, or at any time during the screening period
  • Treatment with 4-AP or 3,4-diaminopyridine (DAP) in any formulation within the 30 days prior to the Screening Visit, or at any time during the screening period
  • History of drug or alcohol abuse (as defined by the Investigator) within the 2 years prior to the Screening Visit, or at any time during the screening period
  • Female subjects who are currently pregnant or who are considering becoming pregnant while participating in the study. Female subjects of childbearing potential who have a positive pregnancy test at either the Screening Visit or Day 1 may not participate in this study
  • Female subjects who are currently breastfeeding
  • Inability to comply with study requirements
  • Current enrollment in any other drug, biological, device, or clinical study
  • Previous participation in this study
  • Any other reason, in the opinion of the Investigator, which would disqualify the subject from participation in this study or make the subject unsuitable for enrollment

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01597297

Locations
Belgium
Research Site
Ath, Belgium
Research Site
Brugge, Belgium
Research Site
Brussels, Belgium
Research Site
Leuven, Belgium
Research Site
Yvoir, Belgium
Canada, Nova Scotia
Research Site
Halifax, Nova Scotia, Canada
Canada, Ontario
Research Site
London, Ontario, Canada
Canada, Quebec
Research Site
Gatineau, Quebec, Canada
Research Site
Greenfield Park, Quebec, Canada
Research Site
Montreal, Quebec, Canada
Italy
Research Site
Ancona, AN, Italy
Research Site
Brescia, BS, Italy
Research Site
Empoli, FI, Italy
Research Site
Palermo, PA, Italy
Research Site
Roma, RM, Italy
Netherlands
Research Site
Breda, Netherlands
Research Site
Sittard-Geleen, Netherlands
Sweden
Research Site
Göteborg, Sweden
Research Site
Stockholm, Sweden
United Kingdom
Research Site
Edgbaston, Birmingham, United Kingdom
Research Site
Poole, Dorset, United Kingdom
Research Site
Swansea, Glamorgan, United Kingdom
Research Site
London, United Kingdom
Sponsors and Collaborators
Biogen Idec
Investigators
Study Director: Medical Director Biogen Idec
  More Information

No publications provided

Responsible Party: Biogen Idec
ClinicalTrials.gov Identifier: NCT01597297     History of Changes
Other Study ID Numbers: 218MS205, 2012-000368-90
Study First Received: May 10, 2012
Last Updated: July 17, 2014
Health Authority: Canada: Ethics Review Committee
Belgium: Federal Agency for Medicinal Products and Health Products
Italy: Ethics Committee
Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)
Sweden: Regional Ethical Review Board
Italy: Ministry of Health
United Kingdom: Research Ethics Committee
Belgium: Institutional Review Board
Sweden: Medical Products Agency
Netherlands: Medicines Evaluation Board (MEB)
Canada: Health Canada
United Kingdom: Medicines and Healthcare Products Regulatory Agency

Additional relevant MeSH terms:
Sclerosis
Multiple Sclerosis
Pathologic Processes
Demyelinating Autoimmune Diseases, CNS
Autoimmune Diseases of the Nervous System
Nervous System Diseases
Demyelinating Diseases
Autoimmune Diseases
Immune System Diseases
4-Aminopyridine
Potassium Channel Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Cardiovascular Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on October 16, 2014